Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2016, Article ID 4592768, 7 pages
http://dx.doi.org/10.1155/2016/4592768
Clinical Study

Phase II Trial of Angiotensin-(1-7) for the Treatment of Patients with Metastatic Sarcoma

1Department of Medicine, Section of Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC, USA
2Comprehensive Cancer Center of Wake Forest University, Wake Forest School of Medicine, Winston-Salem, NC, USA
3Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA
4Department of Surgical Sciences, Center for Hypertension and Vascular Research, Wake Forest School of Medicine, Winston-Salem, NC, USA
5Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, USA

Received 25 July 2016; Accepted 20 September 2016

Academic Editor: Shreyaskumar Patel

Copyright © 2016 Paul D. Savage et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Bui-Nguyen, J. E. Butrynski, N. Penel et al., “A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: the TRUSTS trial,” European Journal of Cancer, vol. 51, no. 10, pp. 1312–1320, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. R. G. Maki, J. K. Wathen, S. R. Patel et al., “Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002,” Journal of Clinical Oncology, vol. 25, no. 19, pp. 2755–2763, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. M. L. Hensley, R. Maki, E. Venkatraman et al., “Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial,” Journal of Clinical Oncology, vol. 20, no. 12, pp. 2824–2831, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Agulnik, J. L. Yarber, S. H. Okuno et al., “An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas,” Annals of Oncology, vol. 24, no. 1, pp. 257–263, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Lewin, K. K. Khamly, R. J. Young et al., “A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma,” British Journal of Cancer, vol. 111, no. 12, pp. 2254–2261, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. W. T. A. van der Graaf, J.-Y. Blay, S. P. Chawla et al., “Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial,” The Lancet, vol. 379, no. 9829, pp. 1879–1886, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. E. A. Tallant, D. I. Diz, and C. M. Ferrario, “Antiproliferative actions of angiotensin-(1–7) in vascular smooth muscle,” Hypertension, vol. 34, no. 4, pp. 950–957, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. R. D. Machado, R. A. Santos, and S. P. Andrade, “Opposing actions of angiotensins on angiogenesis,” Life Sciences, vol. 66, no. 1, pp. 67–76, 1999. View at Publisher · View at Google Scholar · View at Scopus
  9. E. A. Tallant and M. A. Clark, “Molecular mechanisms of inhibition of vascular growth by angiotensin-(1-7),” Hypertension, vol. 42, no. 4, pp. 574–579, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. L. Anton, D. C. Merrill, L. A. A. Neves, and K. B. Brosnihan, “Angiotensin-(1–7) inhibits in vitro endothelial cell tube formation in human umbilical vein endothelial cells through the AT1-7 receptor,” Endocrine, vol. 32, no. 2, pp. 212–218, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. E. J. Freeman, G. M. Chisolm, C. M. Ferrario, and E. A. Tallant, “Angiotensin-(1–7) inhibits vascular smooth muscle cell growth,” Hypertension, vol. 28, no. 1, pp. 104–108, 1996. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Menon, D. R. Soto-Pantoja, M. F. Callahan et al., “Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2,” Cancer Research, vol. 67, no. 6, pp. 2809–2815, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. D. R. Soto-Pantoja, J. Menon, P. E. Gallagher, and E. A. Tallant, “Angiotensin-(1–7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor,” Molecular Cancer Therapeutics, vol. 8, no. 6, pp. 1676–1683, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. D. R. Soto-Pantoja, W. J. Petty, P. E. Gallagher, and E. A. Tallant, “Angiotensin-(1-7) inhibits triple negative tumor growth through the inhibition of angiogenesis and a reduction in placental growth factor PlGF,” Cancer Research, vol. 69, no. 2, supplement, abstract 901, 2009. View at Publisher · View at Google Scholar
  15. W. J. Petty, M. Aklilu, V. A. Varela, J. Lovato, P. D. Savage, and A. A. Miller, “Reverse translation of phase I biomarker findings links the activity of angiotensin-(1–7) to repression of hypoxia inducible factor-1α in vascular sarcomas,” BMC Cancer, vol. 12, article 404, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. W. J. Petty, A. A. Miller, T. P. McCoy, P. E. Gallagher, E. A. Tallant, and F. M. Torti, “Phase I and pharmacokinetic study of angiotensin-(1–7), an endogenous antiangiogenic hormone,” Clinical Cancer Research, vol. 15, no. 23, pp. 7398–7404, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Kohara, Y. Tabuchi, P. Senanayake, K. B. Brosnihan, and C. M. Ferrario, “Reassessment of plasma angiotensins measurement: effects of protease inhibitors and sample handling procedures,” Peptides, vol. 12, no. 5, pp. 1135–1141, 1991. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Domont, C. Massard, N. Lassau, J.-P. Armand, A. Le Cesne, and J.-C. Soria, “Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed Malignant Haemangioperyctoma /Solitary Fibrous Tumour,” Investigational New Drugs, vol. 28, no. 2, pp. 199–202, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Stacchiotti, T. Negri, M. Libertini et al., “Sunitinib malate in solitary fibrous tumor (SFT),” Annals of Oncology, vol. 23, no. 12, Article ID mds143, pp. 3171–3179, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. M. S. Park, S. R. Patel, J. A. Ludwig et al., “Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor,” Cancer, vol. 117, no. 21, pp. 4939–4947, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Valentin, C. Fournier, N. Penel et al., “Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO),” Investigational New Drugs, vol. 31, no. 6, pp. 1626–1627, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Constantinidou, R. L. Jones, D. Olmos et al., “Conventional anthracycline-based chemotherapy has limited efficacy in solitary fibrous tumour,” Acta Oncologica, vol. 51, no. 4, pp. 550–554, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Levard, O. Derbel, P. Méeus et al., “Outcome of patients with advanced solitary fibrous tumors: The Centre Léon Bérard Experience,” BMC Cancer, vol. 13, article 109, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. M. C. Chappell, N. T. Pirro, A. Sykes, and C. M. Ferrario, “Metabolism of angiotensin-(1–7) by angiotensin-converting enzyme,” Hypertension, vol. 31, no. 1, pp. 362–367, 1998. View at Publisher · View at Google Scholar · View at Scopus
  25. B. S. Pessoa, P. M. Becher, R. Van Veghel et al., “Effect of a stable angiotensin-(1–7) analogue on progenitor cell recruitment and cardiovascular function post myocardial infarction,” Journal of the American Heart Association, vol. 4, article e001510, 2015. View at Publisher · View at Google Scholar
  26. M. Durik, R. van Veghel, A. Kuipers et al., “The effect of the thioether-bridged, stabilized angiotensin-(1–7) analogue cyclic Ang-(1–7) on cardiac remodeling and endothelial function in rats with myocardial infarction,” International Journal of Hypertension, vol. 2012, Article ID 536426, 8 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. A. J. Ferreira, T. M. Murça, R. A. Fraga-Silva, C. H. Castro, M. K. Raizada, and R. A. Santos, “New cardiovascular and pulmonary therapeutic strategies based on the angiotensin-converting enzyme 2/angiotensin-(1–7)/mas receptor axis,” International Journal of Hypertension, vol. 2012, Article ID 147825, 13 pages, 2012. View at Publisher · View at Google Scholar
  28. L. D. Kluskens, S. A. Nelemans, R. Rink et al., “Angiotensin-(1-7) with thioether bridge: an angiotensin-converting enzyme-resistant, potent angiotensin-(1-7) analog,” Journal of Pharmacology and Experimental Therapeutics, vol. 328, no. 3, pp. 849–854, 2009. View at Publisher · View at Google Scholar · View at Scopus